Illumina in Talks with EU Antitrust Regulators to Divest Grail Ahead of Expected Block

According to informed sources, Illumina, a U.S. life sciences company, is in talks with the EU's antitrust regulator, hoping to divest Grail before the EU vetoes its $7.1 billion acquisition of the company next week.